The first-generation compounds (such as HSN286, HSN334 and HSN356) (Fig. 1) were however not drug-like (high LogP values for example) and were poorly active against AML with secondary FLT3 mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.